Login to Your Account



Amgen and Simcere strike a deal to co-develop four biosimilars in China

By David Ho
Staff Writer

Wednesday, October 4, 2017

HONG KONG Amgen Inc. and Simcere Pharmaceutical Group have entered into an agreement to develop and commercialize four biosimilars for the Chinese market.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription